bit.bio develops synthetic biology technologies for human health, using its opti-ox platform to precisely and consistently reprogram stem cells into human cell types at scale. The company supplies iPSC-derived cells for biomedical research, drug discovery, disease modeling, and cell therapy development. Its offerings include human neuronal, glial, muscle, and liver cells, custom cell development, disease model cells, and CRISPR screening services.
- Founded
- 2016
- Company size
- 51-200
- Headquarters
- Cambridge, England, GB
- Funding
- Venture-backed
Hiring activity
- Open roles
- 0
- Posted in the last 30 days
- 0
Updated 57 days ago
Latest openings
No open roles right now. New postings appear here as we find them.